Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential.

ABSTRACT: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a new drug class designed to treat patients with type 2 diabetes (T2D). However, cardiovascular outcome trials showed that SGLT2i also offer protection against heart failure (HF)-related events and cardiovascular mortality. These benefits appear to be independent of glycaemic control and have recently been demonstrated in the HF population with reduced ejection fraction (HFrEF), with or without T2D. This comprehensive, evidence-based review focuses on the published studies concerning HF outcomes with SGLT2i, discussing issues that may underlie the different results, along with the impact of these new drugs in clinical practice. The potential translational mechanisms behind SGLT2i cardio-renal benefits and the information that ongoing

SUBMITTER: Brito D 

PROVIDER: S-EPMC7242490 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature